Behandlung der Patientinnen mit HER2- (ErbB2-) positivem Mammakarzinom
作者： M. Untch , C. Jackisch
DOI: 10.1007/S00761-009-1648-6
关键词:
摘要: Die Identifikation von prognostischen und pradiktiven Faktoren hat fur die Effektivitat der Therapie bei Brustkrebspatientinnen eine sehr grose Bedeutung. Der epidermale Wachstumsfaktorrezeptor 2 (HER2, ErbB2) wird etwa 20% aller invasiven Mammakarzinome uberexprimiert. Dies ist mit einer schlechten Prognose kurzerem rezidivfreiem Uberleben Gesamtuberleben assoziiert. gegen HER2 gerichtete Antikorper Trastuzumab konnte uber alle Therapielinien hinweg einen meist signifikanten Benefit HER2-positiven Patientinnen im Vergleich zu herkommlichen Therapien demonstrieren. Dennoch gibt es substanzielle Anzahl Patientinnen, nicht auf den ansprechen oder rezidivieren. Fur diese steht dem Tyrosinkinasehemmer Lapatinib, unterschiedlichen Angriffspunkt an HER2-vermittelten Signalkaskade aufweist, weitere Option zur Verfugung. Mogliche synergistische Effekte werden derzeit in grosen randomisierten Studien gepruft, denn bestmogliche Therapiestrategie Mammakarzinomen nach wie vor eindeutig definiert.
springer.com
sci-hub.se 参考文章(65)
Robert W Carlson, Susan J Moench, M Elizabeth H Hammond, Edith A Perez, Harold J Burstein, D Craig Allred, Charles L Vogel, Lori J Goldstein, George Somlo, William J Gradishar, Clifford A Hudis, Mohammad Jahanzeb, Azadeh Stark, Antonio C Wolff, Michael F Press, Eric P Winer, Soonmyung Paik, Britt-Marie Ljung, None, HER2 testing in breast cancer: NCCN Task Force report and recommendations. Journal of The National Comprehensive Cancer Network. ,vol. 4, ,(2006) , 10.6004/JNCCN.2006.2003
Robert W. Carlson, Clifford A. Hudis, Kathy I. Pritchard, Adjuvant Endocrine Therapy in Hormone Receptor-Positive Postmenopausal Breast Cancer: Evolution of NCCN, ASCO, and St Gallen Recommendations Journal of The National Comprehensive Cancer Network. ,vol. 4, pp. 971- 979 ,(2006) , 10.6004/JNCCN.2006.0082
D Slamon, W Eiermann, N Robert, T Pienkowski, M Martin, J Rolski, A Chan, J Mackey, M Liu, T Pinter, V Valero, C Falkson, T Fornander, T Shiftan, S Olsen, M Buyse, T Kiskartalyi, V Landreau, V Wilson, M Press, J Crown, BCIRG006 Investigators, Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study. Cancer Research. ,vol. 69, pp. 62- 62 ,(2009) , 10.1158/0008-5472.SABCS-09-62
Gustavo A Viani, Sergio L Afonso, Eduardo J Stefano, Ligia I De Fendi, Francisco V Soares, Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials BMC Cancer. ,vol. 7, pp. 153- 153 ,(2007) , 10.1186/1471-2407-7-153
Nancy E. Hynes, Heidi A. Lane, ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Reviews Cancer. ,vol. 5, pp. 341- 354 ,(2005) , 10.1038/NRC1609
C. Vogel, M.A. Cobleigh, D. Tripathy, J.C. Gutheil, L.N. Harris, L. Fehrenbacher, D.J. Slamon, M. Murphy, W.F. Novotny, M. Burchmore, S. Shak, S.J. Stewart, First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report. European Journal of Cancer. ,vol. 37, pp. 25- 29 ,(2001) , 10.1016/S0959-8049(00)00405-6
R Rakkhit, K Broglio, F Peintinger, F Cardoso, EO Hanrahan, JK Litton, A Sahin, D Larsimont, F Meric-Bernstam, TA Buchholz, V Valero, RL Theriault, M Piccart, P Ravdin, GN Hortobagyi, AM Gonzalez-Angulo, None, Significant increased recurrence rates among breast cancer patients with HER2-positive, T1a,bN0M0 tumors. Cancer Research. ,vol. 69, pp. 701- ,(2009) , 10.1158/0008-5472.SABCS-701
M Guix, CM Aura, J Jimenez, M Scaltriti, HL Gomez, DC Doval, C Ellis, R Gagnon, Y Liu, M Koehler, J Baselga, Lapatinib is active in patients with HER2-amplified breast tumors expressing p95HER2. Cancer Research. ,vol. 69, pp. 708- ,(2009) , 10.1158/0008-5472.SABCS-708
Valentina Guarneri, Antonio Frassoldati, Paolo Bruzzi, Roberto D'Amico, Maurizio Belfiglio, Annamaria Molino, Oscar Bertetto, Stefano Cascinu, Francesco Cognetti, Angelo Di Leo, Paolo Pronzato, Lucio Crinó, Biagio Agostara, PierFranco Conte, Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278). Clinical Breast Cancer. ,vol. 8, pp. 453- 456 ,(2008) , 10.3816/CBC.2008.N.056
M. Untch, M. Rezai, S. Loibl, P.A. Fasching, J. Huober, H. Tesch, I. Bauerfeind, J. Hilfrich, K. Mehta, G. von Minckwitz, Neoadjuvant treatment of HER2 overexpressing primary breast cancer with trastuzumab given concomitantly to epirubicin/ cyclophosphamide followed by docetaxel ± capecitabine. First analysis of efficacy and safety of the GBG/AGO multicenter intergroup-study “GeparQuattro” Ejc Supplements. ,vol. 6, pp. 47- ,(2008) , 10.1016/S1359-6349(08)70313-6